CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,258,468 |
| 2024-06-13 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $9.32 | $140K | 1,243,468 |
| 2024-06-13 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 770,760 | ||
| 2024-06-11 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $8.45 | $97K | 7,188,563 |
| 2024-06-06 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −50,000 | $9.00 | $450K | 708,738 |
| 2024-06-05 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +100,000 | 908,738 | ||
| 2024-06-05 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −100,000 | 6,326,700 | ||
| 2024-06-05 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +25,000 | 833,738 | ||
| 2024-06-05 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −25,000 | 808,738 | ||
| 2024-06-05 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −50,000 | $8.42 | $421K | 758,738 |
| 2024-06-05 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −25,000 | 6,401,700 | ||
| 2024-06-03 | Burrell Terry-Ann Director | Grant or award | +13,097 | 69,411 | ||
| 2024-06-03 | Burrell Terry-Ann Director | Grant or award · Stock Option (Right to Buy) | +26,193 | 26,193 | ||
| 2024-06-03 | HERSHBERG ROBERT Director | Grant or award | +13,097 | 51,716 | ||
| 2024-06-03 | HERSHBERG ROBERT Director | Grant or award · Stock Option (Right to Buy) | +26,193 | 26,193 | ||
| 2024-06-03 | Borgeson Blake Director | Grant or award | +13,097 | 7,200,010 | ||
| 2024-06-03 | Borgeson Blake Director | Grant or award · Stock Option (Right to Buy) | +26,193 | 26,193 | ||
| 2024-06-03 | Dar Zavain Director | Grant or award | +13,097 | 102,153 | ||
| 2024-06-03 | Dar Zavain Director | Grant or award · Stock Option (Right to Buy) | +26,193 | 26,193 | ||
| 2024-06-03 | Li Dean Y Director | Grant or award | +13,097 | 72,186 |
Page 19 of 41 · 805 trades